ID   STK38_HUMAN             Reviewed;         465 AA.
AC   Q15208; Q503A1;
DT   21-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-APR-2017, entry version 165.
DE   RecName: Full=Serine/threonine-protein kinase 38;
DE            EC=2.7.11.1;
DE   AltName: Full=NDR1 protein kinase;
DE   AltName: Full=Nuclear Dbf2-related kinase 1;
GN   Name=STK38 {ECO:0000312|EMBL:AAH12085.1};
GN   Synonyms=NDR1 {ECO:0000303|PubMed:7761441};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:CAA84485.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LYS-118.
RC   TISSUE=Fetal brain {ECO:0000312|EMBL:CAA84485.1};
RX   PubMed=7761441; DOI=10.1073/pnas.92.11.5022;
RA   Millward T.A., Cron P., Hemmings B.A.;
RT   "Molecular cloning and characterization of a conserved nuclear
RT   serine/threonine protein kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:5022-5026(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [3] {ECO:0000312|EMBL:AAH12085.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta, and Uterus {ECO:0000312|EMBL:AAH12085.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 2-17; 25-44; 51-63; 72-78; 82-97; 110-118;
RP   122-159; 182-239; 248-266; 277-301; 334-391; 394-402 AND 437-454,
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Calvo F., Kolch W.;
RL   Submitted (MAR-2008) to UniProtKB.
RN   [5] {ECO:0000305}
RP   FUNCTION, ENZYME REGULATION, PHOSPHORYLATION AT THR-74; SER-281 AND
RP   THR-444, AND MUTAGENESIS OF THR-74; LYS-118; SER-281 AND THR-444.
RX   PubMed=12493777; DOI=10.1074/jbc.M210590200;
RA   Tamaskovic R., Bichsel S.J., Rogniaux H., Stegert M.R., Hemmings B.A.;
RT   "Mechanism of Ca2+-mediated regulation of NDR protein kinase through
RT   autophosphorylation and phosphorylation by an upstream kinase.";
RL   J. Biol. Chem. 278:6710-6718(2003).
RN   [6] {ECO:0000305}
RP   ENZYME REGULATION, AND INTERACTION WITH MOB1 AND MOB2.
RX   PubMed=15067004; DOI=10.1074/jbc.M401999200;
RA   Devroe E., Erdjument-Bromage H., Tempst P., Silver P.A.;
RT   "Human Mob proteins regulate the NDR1 and NDR2 serine-threonine
RT   kinases.";
RL   J. Biol. Chem. 279:24444-24451(2004).
RN   [7] {ECO:0000305}
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, ENZYME REGULATION,
RP   AND INTERACTION WITH MOB1 AND MOB2.
RX   PubMed=15197186; DOI=10.1074/jbc.M404542200;
RA   Bichsel S.J., Tamaskovic R., Stegert M.R., Hemmings B.A.;
RT   "Mechanism of activation of NDR (nuclear Dbf2-related) protein kinase
RT   by the hMOB1 protein.";
RL   J. Biol. Chem. 279:35228-35235(2004).
RN   [8]
RP   ISGYLATION.
RX   PubMed=16884686; DOI=10.1016/j.bbrc.2006.07.076;
RA   Takeuchi T., Inoue S., Yokosawa H.;
RT   "Identification and Herc5-mediated ISGylation of novel target
RT   proteins.";
RL   Biochem. Biophys. Res. Commun. 348:473-477(2006).
RN   [9]
RP   INTERACTION WITH STK3/MST2 AND MOBKL1B, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION BY STK3/MST2.
RX   PubMed=18362890; DOI=10.1038/onc.2008.66;
RA   Hirabayashi S., Nakagawa K., Sumita K., Hidaka S., Kawai T., Ikeda M.,
RA   Kawata A., Ohno K., Hata Y.;
RT   "Threonine 74 of MOB1 is a putative key phosphorylation site by MST2
RT   to form the scaffold to activate nuclear Dbf2-related kinase 1.";
RL   Oncogene 27:4281-4292(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION IN THE MLL5-L COMPLEX.
RX   PubMed=19377461; DOI=10.1038/nature07954;
RA   Fujiki R., Chikanishi T., Hashiba W., Ito H., Takada I., Roeder R.G.,
RA   Kitagawa H., Kato S.;
RT   "GlcNAcylation of a histone methyltransferase in retinoic-acid-induced
RT   granulopoiesis.";
RL   Nature 459:455-459(2009).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MAP3K1 AND
RP   MAP3K2.
RX   PubMed=17906693; DOI=10.1038/sj.onc.1210828;
RA   Enomoto A., Kido N., Ito M., Morita A., Matsumoto Y., Takamatsu N.,
RA   Hosoi Y., Miyagawa K.;
RT   "Negative regulation of MEKK1/2 signaling by serine-threonine kinase
RT   38 (STK38).";
RL   Oncogene 27:1930-1938(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-264, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-264, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17] {ECO:0000305}
RP   STRUCTURE BY NMR OF 62-84, ENZYME REGULATION, AND INTERACTION WITH
RP   S100B.
RX   PubMed=14661952; DOI=10.1021/bi035089a;
RA   Bhattacharya S., Large E., Heizmann C.W., Hemmings B.A., Chazin W.J.;
RT   "Structure of the Ca2+/S100B/NDR kinase peptide complex: insights into
RT   S100 target specificity and activation of the kinase.";
RL   Biochemistry 42:14416-14426(2003).
RN   [18]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-18; ASN-145 AND ARG-267.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Negative regulator of MAP3K1/2 signaling. Converts
CC       MAP3K2 from its phosphorylated form to its non-phosphorylated form
CC       and inhibits autophosphorylation of MAP3K2.
CC       {ECO:0000269|PubMed:12493777, ECO:0000269|PubMed:15197186,
CC       ECO:0000269|PubMed:17906693, ECO:0000269|PubMed:7761441}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Activated by binding of S100B which releases
CC       autoinhibitory N-lobe interactions, enabling ATP to bind and the
CC       autophosphorylation of Ser-281. Thr-444 then undergoes calcium-
CC       dependent phosphorylation by STK24/MST3. Interactions between
CC       phosphorylated Thr-444 and the N-lobe promote additional
CC       structural changes that complete the activation of the kinase.
CC       Autoinhibition is also released by the binding of MOB1/MOBKL1A and
CC       MOB2/HCCA2 to the N-terminal of STK38.
CC       {ECO:0000269|PubMed:12493777, ECO:0000269|PubMed:14661952,
CC       ECO:0000269|PubMed:15067004, ECO:0000269|PubMed:15197186}.
CC   -!- SUBUNIT: Interacts with MICAL1; leading to inhibit the protein
CC       kinase activity by antagonizing activation by MST1/STK4 (By
CC       similarity). Homodimeric S100B binds two molecules of STK38.
CC       Component of the MLL5-L complex, at least composed of KMT2E/MLL5,
CC       STK38, PPP1CA, PPP1CB, PPP1CC, HCFC1, ACTB and OGT. Interacts with
CC       MOB1 and MOB2. Interacts with MAP3K1 and MAP3K2 (via the kinase
CC       catalytic domain). Forms a tripartite complex with MOBKL1B and
CC       STK3/MST2. {ECO:0000250, ECO:0000269|PubMed:14661952,
CC       ECO:0000269|PubMed:15067004, ECO:0000269|PubMed:15197186,
CC       ECO:0000269|PubMed:17906693, ECO:0000269|PubMed:18362890,
CC       ECO:0000269|PubMed:19377461}.
CC   -!- INTERACTION:
CC       P49407:ARRB1; NbExp=3; IntAct=EBI-458376, EBI-743313;
CC       P32121:ARRB2; NbExp=3; IntAct=EBI-458376, EBI-714559;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-458376, EBI-352572;
CC       Q9H8S9:MOB1A; NbExp=3; IntAct=EBI-458376, EBI-748229;
CC       P02638:S100B (xeno); NbExp=3; IntAct=EBI-458376, EBI-458452;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed with highest levels
CC       observed in peripheral blood leukocytes.
CC       {ECO:0000269|PubMed:15197186, ECO:0000269|PubMed:7761441}.
CC   -!- PTM: ISGylated. {ECO:0000305|PubMed:16884686}.
CC   -!- PTM: Phosphorylated by STK3/MST2 and this is enhanced by MOBKL1B.
CC       {ECO:0000269|PubMed:12493777, ECO:0000269|PubMed:18362890}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z35102; CAA84485.1; -; mRNA.
DR   EMBL; Z85986; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012085; AAH12085.1; -; mRNA.
DR   EMBL; BC095413; AAH95413.1; -; mRNA.
DR   CCDS; CCDS4822.1; -.
DR   PIR; I38133; I38133.
DR   RefSeq; NP_001292031.1; NM_001305102.1.
DR   RefSeq; NP_009202.1; NM_007271.3.
DR   RefSeq; XP_006715051.1; XM_006714988.3.
DR   RefSeq; XP_006715052.1; XM_006714989.3.
DR   UniGene; Hs.409578; -.
DR   PDB; 1PSB; NMR; -; C/D=62-87.
DR   PDBsum; 1PSB; -.
DR   ProteinModelPortal; Q15208; -.
DR   SMR; Q15208; -.
DR   BioGrid; 116457; 49.
DR   IntAct; Q15208; 16.
DR   MINT; MINT-1217042; -.
DR   STRING; 9606.ENSP00000229812; -.
DR   BindingDB; Q15208; -.
DR   ChEMBL; CHEMBL1075155; -.
DR   GuidetoPHARMACOLOGY; 1517; -.
DR   iPTMnet; Q15208; -.
DR   PhosphoSitePlus; Q15208; -.
DR   BioMuta; STK38; -.
DR   DMDM; 56749457; -.
DR   EPD; Q15208; -.
DR   MaxQB; Q15208; -.
DR   PaxDb; Q15208; -.
DR   PeptideAtlas; Q15208; -.
DR   PRIDE; Q15208; -.
DR   DNASU; 11329; -.
DR   Ensembl; ENST00000229812; ENSP00000229812; ENSG00000112079.
DR   GeneID; 11329; -.
DR   KEGG; hsa:11329; -.
DR   UCSC; uc003omh.3; human.
DR   CTD; 11329; -.
DR   DisGeNET; 11329; -.
DR   GeneCards; STK38; -.
DR   HGNC; HGNC:17847; STK38.
DR   HPA; CAB004673; -.
DR   HPA; HPA038623; -.
DR   HPA; HPA051324; -.
DR   MIM; 606964; gene.
DR   neXtProt; NX_Q15208; -.
DR   OpenTargets; ENSG00000112079; -.
DR   PharmGKB; PA38251; -.
DR   eggNOG; KOG0605; Eukaryota.
DR   eggNOG; ENOG410XQC0; LUCA.
DR   GeneTree; ENSGT00760000118994; -.
DR   HOGENOM; HOG000233033; -.
DR   HOVERGEN; HBG104247; -.
DR   InParanoid; Q15208; -.
DR   KO; K08790; -.
DR   OMA; QPIPERN; -.
DR   OrthoDB; EOG091G028J; -.
DR   PhylomeDB; Q15208; -.
DR   TreeFam; TF105337; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   SignaLink; Q15208; -.
DR   SIGNOR; Q15208; -.
DR   ChiTaRS; STK38; human.
DR   EvolutionaryTrace; Q15208; -.
DR   GeneWiki; STK38; -.
DR   GenomeRNAi; 11329; -.
DR   PRO; PR:Q15208; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000112079; -.
DR   CleanEx; HS_STK38; -.
DR   ExpressionAtlas; Q15208; baseline and differential.
DR   Genevisible; Q15208; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006464; P:cellular protein modification process; IDA:ProtInc.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000269|Ref.4}.
FT   CHAIN         2    465       Serine/threonine-protein kinase 38.
FT                                /FTId=PRO_0000086718.
FT   DOMAIN       89    382       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000312|EMBL:CAA84485.1}.
FT   DOMAIN      383    455       AGC-kinase C-terminal.
FT   NP_BIND      95    103       ATP. {ECO:0000250|UniProtKB:O95835,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   REGION       62     87       Interaction with S100B.
FT                                {ECO:0000269|PubMed:14661952}.
FT   ACT_SITE    212    212       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     118    118       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:12493777,
FT                                ECO:0000269|PubMed:7761441}.
FT   MOD_RES       2      2       N-acetylalanine. {ECO:0000269|Ref.4}.
FT   MOD_RES      74     74       Phosphothreonine.
FT                                {ECO:0000269|PubMed:12493777}.
FT   MOD_RES     264    264       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     281    281       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12493777}.
FT   MOD_RES     444    444       Phosphothreonine; by STK24/MST3.
FT                                {ECO:0000269|PubMed:12493777}.
FT   VARIANT      18     18       E -> K (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041196.
FT   VARIANT     145    145       D -> N (in dbSNP:rs56005153).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041197.
FT   VARIANT     267    267       K -> R (in dbSNP:rs56105564).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041198.
FT   MUTAGEN      74     74       T->A: Decreases autophosphorylation and
FT                                kinase activity. Reduced binding of
FT                                S100B. {ECO:0000269|PubMed:12493777}.
FT   MUTAGEN     118    118       K->A: Loss of autophosphorylation and
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:12493777,
FT                                ECO:0000269|PubMed:7761441}.
FT   MUTAGEN     281    281       S->A: Loss of autophosphorylation and
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:12493777}.
FT   MUTAGEN     444    444       T->A: Decreases autophosphorylation and
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:12493777}.
FT   HELIX        74     85       {ECO:0000244|PDB:1PSB}.
SQ   SEQUENCE   465 AA;  54190 MW;  7262221DBFFAF83C CRC64;
     MAMTGSTPCS SMSNHTKERV TMTKVTLENF YSNLIAQHEE REMRQKKLEK VMEEEGLKDE
     EKRLRRSAHA RKETEFLRLK RTRLGLEDFE SLKVIGRGAF GEVRLVQKKD TGHVYAMKIL
     RKADMLEKEQ VGHIRAERDI LVEADSLWVV KMFYSFQDKL NLYLIMEFLP GGDMMTLLMK
     KDTLTEEETQ FYIAETVLAI DSIHQLGFIH RDIKPDNLLL DSKGHVKLSD FGLCTGLKKA
     HRTEFYRNLN HSLPSDFTFQ NMNSKRKAET WKRNRRQLAF STVGTPDYIA PEVFMQTGYN
     KLCDWWSLGV IMYEMLIGYP PFCSETPQET YKKVMNWKET LTFPPEVPIS EKAKDLILRF
     CCEWEHRIGA PGVEEIKSNS FFEGVDWEHI RERPAAISIE IKSIDDTSNF DEFPESDILK
     PTVATSNHPE TDYKNKDWVF INYTYKRFEG LTARGAIPSY MKAAK
//
